MA45671A - Anticorps antivirus zika et procédés d'utilisation - Google Patents

Anticorps antivirus zika et procédés d'utilisation

Info

Publication number
MA45671A
MA45671A MA045671A MA45671A MA45671A MA 45671 A MA45671 A MA 45671A MA 045671 A MA045671 A MA 045671A MA 45671 A MA45671 A MA 45671A MA 45671 A MA45671 A MA 45671A
Authority
MA
Morocco
Prior art keywords
zika
methods
antivirus antibodies
antivirus
antibodies
Prior art date
Application number
MA045671A
Other languages
English (en)
Inventor
Christos Kyratsous
Peter Mason
William Olson
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA45671A publication Critical patent/MA45671A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045671A 2016-07-18 2017-07-17 Anticorps antivirus zika et procédés d'utilisation MA45671A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662363546P 2016-07-18 2016-07-18
US201762474753P 2017-03-22 2017-03-22

Publications (1)

Publication Number Publication Date
MA45671A true MA45671A (fr) 2021-04-07

Family

ID=59416830

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045671A MA45671A (fr) 2016-07-18 2017-07-17 Anticorps antivirus zika et procédés d'utilisation

Country Status (19)

Country Link
US (2) US10421804B2 (fr)
EP (1) EP3484917A1 (fr)
JP (1) JP6993401B2 (fr)
KR (1) KR20190030206A (fr)
CN (1) CN109641952A (fr)
AU (1) AU2017300277A1 (fr)
BR (1) BR112019000798A2 (fr)
CA (1) CA3030618A1 (fr)
CL (1) CL2019000124A1 (fr)
CO (1) CO2019000968A2 (fr)
IL (1) IL263818A (fr)
MA (1) MA45671A (fr)
MX (1) MX2019000761A (fr)
PH (1) PH12018502673A1 (fr)
SG (1) SG11201811363YA (fr)
TW (1) TW201815821A (fr)
UY (1) UY37336A (fr)
WO (1) WO2018017497A1 (fr)
ZA (1) ZA201808603B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
WO2016161010A2 (fr) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Régions constantes de chaînes lourdes présentant une liaison réduite aux récepteurs fc gamma
KR102777500B1 (ko) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
WO2018010789A1 (fr) 2016-07-13 2018-01-18 Humabs Biomed Sa Nouveaux anticorps se liant spécifiquement aux épitopes du virus zika et leurs utilisations
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
GB2579940B (en) * 2017-08-03 2022-11-30 Antheia Inc Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids
WO2019042555A1 (fr) 2017-08-31 2019-03-07 Humabs Biomed Sa Anticorps multispécifiques se liant spécifiquement aux épitopes du virus zika et leurs utilisations
CA3093729A1 (fr) * 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anticorps diriges contre le virus de la dengue presentant une reactivite croisee au virus zika et procedes d'utilisation
WO2019204654A1 (fr) 2018-04-18 2019-10-24 Utah State University Compositions et procédés de caractérisation et de développement de vaccins contre le virus zika
US11884718B2 (en) 2018-04-24 2024-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
PT3844189T (pt) 2018-08-31 2025-01-29 Regeneron Pharma Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
WO2020061159A1 (fr) * 2018-09-20 2020-03-26 Vanderbilt University Anticorps humains contre le virus zika
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
JP7524214B2 (ja) * 2019-04-03 2024-07-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物
CN111100201B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体
CN111138534B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 寨卡病毒囊膜蛋白的鼠源单克隆抗体
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2021236225A1 (fr) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Procédé de détection d'anticorps spécifiques du virus zika
US20230324404A1 (en) 2020-05-20 2023-10-12 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2022001803A1 (fr) * 2020-06-28 2022-01-06 神州细胞工程有限公司 Méthode permettant de réduire un effet d'ade viral

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008140603A2 (fr) 2006-12-08 2008-11-20 Macrogenics, Inc. MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
TW200838550A (en) 2007-02-09 2008-10-01 Novartis Ag Organic compounds
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
EP2895513B1 (fr) 2012-09-12 2018-05-23 Genzyme Corporation Polypeptides comprenants le domaine fc ayant une glycosylation modifiee et une fonction effecteur reduite
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
JO3701B1 (ar) * 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法

Also Published As

Publication number Publication date
ZA201808603B (en) 2019-08-28
KR20190030206A (ko) 2019-03-21
BR112019000798A2 (pt) 2019-07-02
WO2018017497A1 (fr) 2018-01-25
US20180016324A1 (en) 2018-01-18
SG11201811363YA (en) 2019-01-30
CL2019000124A1 (es) 2019-04-05
CA3030618A1 (fr) 2018-01-25
TW201815821A (zh) 2018-05-01
AU2017300277A1 (en) 2019-02-07
MX2019000761A (es) 2019-07-04
PH12018502673A1 (en) 2019-11-11
EP3484917A1 (fr) 2019-05-22
US10421804B2 (en) 2019-09-24
JP2019528050A (ja) 2019-10-10
JP6993401B2 (ja) 2022-02-04
US11117955B2 (en) 2021-09-14
US20200062831A1 (en) 2020-02-27
UY37336A (es) 2018-02-28
IL263818A (en) 2019-01-31
CO2019000968A2 (es) 2019-04-30
CN109641952A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3634430A4 (fr) Agents multibiotiques et procédés d'utilisation de ceux-ci
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
MA42979A (fr) Anticorps anti-age et procédés d'utilisation correspondants
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
EP3472316A4 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3491025A4 (fr) Anticorps fcrn et leurs procédés d'utilisation